Mounjaro and Zepbound Are Great, but This Is the Real Reason Why Eli Lilly Can Soar Past a $1 Trillion Valuation [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
It has a couple of fantastic products in Zepbound, which is approved for weight loss, and Mounjaro, which is essentially the same thing but is approved to treat diabetes. Between the two of them, the company is sitting on a gold mine, with their combined peak annual revenue potentially topping more than $50 billion. That's not too bad for a company that generated less than $35 billion in all of last year. But as promising as those products may be, they aren't why I think Eli Lilly can hit a $1 trillion market capitalization and keep going higher. Instead, it's management's outlook for the future and its long-term strategy that should have investors bullish on the road ahead. This can still be an excellent stock to buy, even at what may seem like a hugely inflated valuation. Eli Lilly looks to "exploit" its lead Being the top company in the anti-obesity market and the most valuable healthcare company in the world is impressive, but staying in those positions is going to be diffic
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly Targets IBD, Takes Calculated Gamble With $3.2bn Morphic Deal [Seeking Alpha]Seeking Alpha
- GordonMD® Global Investments Portfolio Company, Radionetics Oncology, Announced Strategic Agreement with Lilly [Yahoo! Finance]Yahoo! Finance
- GordonMD® Global Investments Portfolio Company, Radionetics Oncology, Announced Strategic Agreement with LillyBusiness Wire
- 3 No-Brainer Stocks to Buy in July [Yahoo! Finance]Yahoo! Finance
- Myricx Bio gains $114m in Series A round to develop NMTi-ADCs [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 4/30/24 - Beat
LLY
Sec Filings
- 7/8/24 - Form 4
- 7/3/24 - Form 4
- 7/2/24 - Form 4
- LLY's page on the SEC website